Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis

Bieber, Thomas; Vick, K.; Fölster‐Holst, Regina; Fortina, Anna Belloni; Städtler, G.; Worm, Margitta; Arcangeli, Fabio

doi:10.1111/j.1398-9995.2006.01269.x

Cited by 87 publications

(64 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, MPA was superior to tacrolimus in terms of itching, EASI score and sleep quality. 42 The authors of this study therefore concluded that these advantages recommended the use of MPA as first line treatment in AD. Patients who recovered from AD flares had a 3.5-fold lower risk of relapse with maintenance therapy of twice-daily emollient applications plus MPA (0.1%) ointment (applied once daily at weekends only) than with emollient alone.…”

Section: Efficacy Of Mpa In Admentioning

confidence: 94%

“…43 Among patients with severe AD flares, 67% of patients were clear of or experienced significant improvement in symptoms (according to Investigator's Global Assessment) after 3 weeks of treatment with MPA 0.1% ointment applied once daily, the same percentage as in patients treated with tacrolimus 0.03% ointment twice daily. 42 A notable 70% improvement [mean visual analogue scale score (VAS)] in itching was reported after 7 days' treatment, which was reflected in better quality of sleep and a 90% improvement in Eczema Area and Severity Index (EASI) scores by end of treatment. Indeed, MPA was superior to tacrolimus in terms of itching, EASI score and sleep quality.…”

Section: Efficacy Of Mpa In Admentioning

confidence: 97%

“…39 Once-daily MPA has demonstrated good efficacy, with rapid onset of activity in a wide range of patients with AD. [41][42][43] In infants aged <18 months, 85% treated with a milk formulation of MPA experienced complete remission or significant improvement of AD after 3 weeks. 41 Vesiculation was completely absent after 1 week of treatment and no patient had exudation after 3 weeks.…”

Section: Efficacy Of Mpa In Admentioning

confidence: 99%

See 2 more Smart Citations

Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate

Luger

2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

Although emollients can be sufficient to manage mild atopic dermatitis (AD), acute flares resulting in moderate-to-severe symptoms require treatment with anti-inflammatory agents, such as topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs). This review examines the role of a member of the newest class of TCs, the fourth-generation compound methylprednisolone aceponate (MPA) in AD management, with reference to the chemical structure, pharmacokinetics, efficacy in AD, safety assessed in preclinical and clinical trials and dosing considerations. MPA has an optimized efficacy/safety profile with minimal local or systemic adverse effects. In addition, it offers the opportunity for once-daily dosing, which provides benefits in terms of patient compliance with treatment.

show abstract

Section: Efficacy Of Mpa In Admentioning

confidence: 94%

Section: Efficacy Of Mpa In Admentioning

confidence: 97%

Section: Efficacy Of Mpa In Admentioning

confidence: 99%

See 1 more Smart Citation

Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate

Luger

2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The remaining 21 articles met all entry criteria and were included in the network meta-analysis. Among these studies, 3 articles were dual submissions and 1 study was divided into two comparisons; thus, only 19 [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25] treatment comparisons were included. The screening process is illustrated in figure 2.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis

Huang

2015

Dermatology

View full text Add to dashboard Cite

Objective: Using a network meta-analysis, we aimed to compare the efficacy and safety of tacrolimus and pimecrolimus as treatment options for children with atopic dermatitis (AD). Methods: Randomized controlled studies with a modified Jadad score >3 using tacrolimus or pimecrolimus in pediatric patients with AD were studied. Results: Out of 163 articles, 19 studies enrolling a total of 6,413 pediatric patients were selected. Pooled analysis revealed that tacrolimus 0.03% or 0.1% and pimecrolimus 1% were better at reducing eczema compared with vehicles. No significance was found between tacrolimus and pimecrolimus in improving the severity of eczema. More patients tended to withdraw in the vehicle groups compared to the tacrolimus and pimecrolimus groups. No significant difference existed between total adverse events and withdrawals in the tacrolimus and pimecrolimus groups. Conclusions: Pimecrolimus was similar to tacrolimus in both efficacy and safety for AD in children, but both were better than vehicles.

show abstract

“…По EASI, зуду и качеству сна эф-фект МПА был достоверно выше. Общий показа-тель цена/качество также значительно выше у МПА [22].…”

Section: клиническая дерматология и венерология 6 2015unclassified

Topical glucocorticosteroid and 2% urea as a new topical therapeutic agent used to treat chronic dermatoses

Филимонкова¹,

Bahlykova²

2015

Klin. dermatol. venerol.

View full text Add to dashboard Cite

Проблема топической терапии больных хрони-ческими дерматозами остается одной из актуальных в современной дерматологии, несмотря на результа-ты значительного числа исследовательских работ [1, doi: 10.17116/klinderma201514635-40 Топический глюкокортикостероид и 2% мочевина -новое средство наружной терапии хронических дерматозов Стероидчувствительные дерматозы являются важной медико-социальной проблемой, актуальность которой определяется неуклонным ростом заболеваемости, их хроническим рецидивирующим течением и сложностью в выборе метода лечения. Применение глюкокортикостероидных (ГКС) средств, оказывающих комплексное противовоспалительное, противоаллергическое, противозудное действие, является основным принципом наружной терапии стероидчувствительных дерматозов. Несмотря на большое количество различных топических ГКС в арсенале дерматолога, сохраняется актуальность поиска и вывода на рынок новых препаратов. Цель -обзор литературы по современным аспектам наружной терапии стероидчувствительных дерматозов, изучение исследований по ГКС последнего поколения -метилпреднизолона ацепонат (МПА) и компоненту натурального увлажняющего фактора -мочевине. Материал и методы. Работа выполнена на базе ФГБУ «Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии» Минздрава России. Результаты. Данные многих исследований доказали высокую клиническую эффективность МПА, его безопасность, обусловленную отсутствием галогенов хлора и фтора, биоактивацией в очаге воспаления, минимальной системной абсорбцией и удобством применения (1 раз в сутки). Также при наружном лечении хронических воспалительных дерматозов активно используется средство, обладающее выраженным увлажняющим, смягчающим и антисептическим действием -мочевина. Заключение. Полученные выводы исследований и практический опыт применения нового комбинированного лекарственного препарата -крема Комфодерм М 2 , содержащего комбинацию МПА и 2% мочевины, показали возможность применения данного средства на участках с тонкой чувствительной кожей (лицо, шея, складки) и в интермиттирующих программах. Ключевые слова: топическая терапия хронических дерматозов, метилпреднизолона ацепонат, 2% мочевина, Комфодерм М 2 .The steroid-sensitive dermatoses pose an important medical and social problem, whose relevance is determined by the steady growth of the incidence, chronic relapsing course, and complexity of treatment choice. Application of glucocorticosteroids (GCS) that have complex anti-inflammatory, antiallergic, and antipruritic effect is the basic principle of external therapy of steroidsensitive dermatoses. Despite the wide variety of various topical corticosteroids in the arsenal of a dermatologist, the discovery and market launch of new drug products is still relevant. Objective. This study is aimed at reviewing the literature on the modern aspects of the topical therapy of the steroid-sensitive dermatoses, the study of the investigations on the methylprednisolone aceponate (MPA), the new-generation GCS, and urea, the natural moisturizing factor. Material ...

show abstract

Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis

Cited by 87 publications

References 10 publications

Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate

Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate

Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis

Topical glucocorticosteroid and 2% urea as a new topical therapeutic agent used to treat chronic dermatoses

Contact Info

Product

Resources

About